Experimental Physiology Celebrating 100 years
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Experimental Physiology 90.3 pp 307-313
DOI: 10.1113/expphysiol.2005.030403
© The Physiological Society 2005
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
90/3/307    most recent
expphysiol.2005.030403v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Morishita, R.
Right arrow Articles by Ogihara, T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Morishita, R.
Right arrow Articles by Ogihara, T.
Related Collections
Right arrow Themed Issue papers
Right arrow Cardiovascular control

Themed Issue papers

Cardiovascular Genomics

Does gene therapy become pharmacotherapy?

Ryuichi Morishita1, Motokuni Aoki2 and Toshio Ogihara2

1 Division of Clinical Gene Therapy2 Department of Geriatric Medicine, Graduate School of Medicine, Osaka University, Suita 565-0871, Japan

Recent progress in molecular and cellular biology has led to the development of numerous effective cardiovascular drugs. However, there are still a number of diseases for which no known effective therapy exists, such as peripheral arterial disease, ischaemic heart disease, restenosis after angioplasty, and vascular bypass graft occlusion. Currently, gene therapy is emerging as a potential strategy for the treatment of cardiovascular disease despite its limitations. The first human trial in gene therapy for cardiovascular disease was started at 1994 to treat peripheral vascular disease using vascular endothelial growth factor (VEGF). Then, many different potent angiogenic growth factors were tested in clinical trials to treat peripheral arterial disease and ischaemic heart disease. Improvement of clinical symptoms in peripheral arterial disease and ischaemic heart disease has been reported. This review focuses on the future potential of gene therapy for the treatment of cardiovascular disease. In the future, gene therapy might become a real pharmacotherapy to treat cardiovascular disease.

(Received 3 March 2005; accepted after revision 9 March 2005; first published online 18 March 2005)
Corresponding author R. Morishita: Division of Clinical Gene Therapy, Graduate School of Medicine, Osaka University, 2-2 Yamada-oka, Suita 565-0871, Japan. Email: morishit{at}cgt.med.osaka-u.ac.jp






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2005 by the The Physiological Society.